New Application Templates by JMAFF

With the revision of the Pharmaceuticals and Medical Devices Act (PMD Act) on August 1, 2021, some procedures for the pharmaceutical system of manufacturing and marketing of veterinary drugs, etc. have been changed.

Some application forms for manufacturing, manufacturing and marketing, foreign manufacturer accreditation for veterinary drugs, veterinary medical devices, in vitro diagnostic kits, etc. have been partially changed. Please be careful.

2020 Global Benchmarking Survey Overview Report

The HealthforAnimals Global Benchmarking Survey is run every 5 years and has now grown to include 11 countries in the 2020 survey. The purpose is to examine the interactions between industry and regulatory systems for veterinary medicinal products, particularly the impact of regulations on the animal health industry’s ability to access markets, be innovative, continue to commercialise existing products and be competitive. 

You can download the report below:

“2020 Global Benchmarking Survey Overview Report” の続きを読む

Senju Pharmaceutical launched “IDU Senju®” eye drops for feleine herpesvirus through DS Pharma Animal Health.

Osaka-based Senju Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Osaka, President: Shuhei Yoshida, hereinafter “Senju Pharmaceutical”) and DS Pharma Animal Health Co., Ltd. will release “IDU Senju (R) “, an eye drops for cat herpesvirus infections, which Senju Pharmaceutical obtained marketing approval in December 2020, and will release it on May 19, 2021.

“Senju Pharmaceutical launched “IDU Senju®” eye drops for feleine herpesvirus through DS Pharma Animal Health.” の続きを読む

DS Pharma Animal Health Announces World’s First Marketing Authorization Approval for a Canine Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cell Product, Stemcure®

DS Pharma Animal Health Co., Ltd. (Head Office: Chuo-ku, Osaka, Japan; President & CEO: Kazuhiro Takada) announced today that it received marketing authorization on March 19 for Stemcure® (development code: A-110), a canine allogeneic adipose tissue-derived mesenchymal stem cell product that is classified as a veterinary regenerative medical product (animal somatic stem cell-processed product). This is the world’s first authorization approval for the manufacture and marketing of a veterinary regenerative medical product whose main ingredient is canine allogeneic adipose tissue-derived mesenchymal stem cells.

You can download the press release from the link below:

Animal Health Innovation Asia 2020

We succesfully had a virtual event of Animal Health Innovation Asia 2020 by Kisaco Research. November 25th was Japan Day, and thanks to Mr. Calan Smith, I was honored to host 3 programs, i.e. “Panel Discussion” by Messrs. Kato, Fukui and Hagihara who are industry leaders from Zoetis JapanZenoaq, and Kyoritsu Seiyaku, respectively, “Innovation Showcase” by 4 start-ups, such as Toletta CatsMT3, Vetamic (Nihon Univ.), and KAICO, and “University Pavilion” by 3 universities, such as Prof. Mizuno of Yamaguchi Univ., Assoc. Prof. Isaka of Rakuno Gakuen Univ., and Dr. Kato of Tokyo Univ. of Marine Science and Technology.
We hope that we can have an offline event, not a virtual one, in Tokyo in 2021.

“Animal Health Innovation Asia 2020” の続きを読む

Current situation and Future of Veterinary Medicines and Related Industries in Japan and the US – New Technologies that Change Future –

The captioned article has been written by Dr. Yuki Ujimasa, DVM, MS, President of AHRMS, Inc., and published on the Journal of the Japan Veterinary Medical Association since October 2019. It recently became public via the following link:
Sorry to say, it is described only in Japanese. The chapters of the article are as follows:
1. Recent activities by multi-national animal health pharmaceutical companies and domestic companies
2. New technologies that can change husbandry industries
3. Impact of emerging and re-emerging infectious diseases in food animals and Possibilities of plant-based meat and cultured meat
4. Telemedicine in veterinary medicines
5. Changes of distribution system and home-delivery in companion animal medicines
6. Necessity for review of veterinary advertising regulations
7. Conclusions
8. Acknowledgment